DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma
(MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China